Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?

Immune checkpoint inhibitors (ICIs) have significantly altered the treatment landscape for cancer in the last decade. However, their benefits are often offset by therapy-limiting immune-related adverse events (irAEs). Acute interstitial nephritis (AIN) is the most common renal irAE, but the exact me...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Hui Zhuan, Sprangers, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616439/
https://www.ncbi.nlm.nih.gov/pubmed/37915924
http://dx.doi.org/10.1093/ckj/sfad205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616439/
https://www.ncbi.nlm.nih.gov/pubmed/37915924
http://dx.doi.org/10.1093/ckj/sfad205

Ejemplares similares